Characterization of T cell epitopes of the receptor for hyaluronic acid mediated motility (RHAMM/CD168) in acute myeloid leukemia.

被引：0
|
作者：
Schmitt, M
Li, L
Ringhoffer, M
Barth, T
Wiesneth, M
Dohner, H
Greiner, J
机构：
[1] Univ Ulm, Dept Internal Med 3, D-7900 Ulm, Germany
[2] Univ Ulm, Inst Pathol, D-7900 Ulm, Germany
[3] German Red Cross, Inst Immunogenet & Clin Transfus Med, Ulm, Germany
来源：
BLOOD | 2004年 / 104卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2540
引用
收藏
页码：696A / 696A
页数：1
相关论文
共 50 条
  • [1] Identification and characterization of epitopes of the receptor for hyaluronic acid-mediated motility (RHAMM/CD168) recognized by CD8+ T cells of HLA-A2-positive patients with acute myeloid leukemia
    Greiner, J
    Li, L
    Ringhoffer, M
    Barth, TFE
    Giannopoulos, K
    Guillaume, P
    Ritter, G
    Wiesneth, M
    Döhner, H
    Schmitt, M
    BLOOD, 2005, 106 (03) : 938 - 945
  • [2] The receptor for hyaluronic acid mediated motility (RHAMM/CD168) is a potential target for immunotherapy of patients with B-Cell chronic lymphocytic leukemia.
    Giannopoulos, K
    Hus, I
    Li, L
    Bojarska-Junak, A
    Greiner, J
    Rolinski, J
    Dmoszynska, A
    Doehner, H
    Schmitt, M
    BLOOD, 2005, 106 (11) : 20A - 20A
  • [3] The receptor for hyaluronic acid mediated motility (RHAMM/CD168) is a leukemia associated antigen eliciting both humoral and cellular immune responses in patients with acute myeloid leukemia (AML)
    J Greiner
    M Ringhoffer
    L Li
    T Barth
    T Wölfel
    H Döhner
    M Schmitt
    Cancer Cell International, 4 (Suppl 1)
  • [4] Identification and validation of Osteopontin and receptor for hyaluronic acid-mediated motility (RHAMM, CD168) for potential immunotherapeutic significance of in lung squamous cell carcinoma
    Gao, Shan
    Li, Meihe
    Kang, Minchao
    Zhao, Rui
    Wen, Xiaopeng
    Zhang, Guangjian
    Zheng, Jin
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2022, 107
  • [5] RHAMM/HMMR (CD168) is not an ideal target antigen for immunotherapy of acute myeloid leukemia
    Snauwaert, Sylvia
    Vanhee, Stijn
    Goetgeluk, Glenn
    Verstichel, Greet
    Van Caeneghem, Yasmine
    Velghe, Imke
    Philippe, Jan
    Berneman, Zwi N.
    Plum, Jean
    Taghon, Tom
    Leclercq, Georges
    Thielemans, Kris
    Kerre, Tessa
    Vandekerckhove, Bart
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2012, 97 (10): : 1539 - 1547
  • [6] The Receptor for Hyaluronan-Mediated Motility (RHAMM, CD168) Contributes to the Development of Bronchopulmonary Dysplasia
    Chen, I.
    Liao, J.
    Cheong, N.
    Longoria, C. L.
    Savani, R. C.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2019, 199
  • [7] Receptor for hyaluronic acid-mediated motility (RHAMM, CD168) expression is prognostically important in both nodal negative and nodal positive large cell lung cancer
    Augustin, Florian
    Fiegl, Michael
    Schmid, Thomas
    Pomme, Geoffrey
    Sterlacci, William
    Tzankov, Alexandar
    JOURNAL OF CLINICAL PATHOLOGY, 2015, 68 (05) : 368 - 373
  • [8] RHAMM/CD168 is a novel leukemia associated antigen with prognostic value for patients with B-cell chronic lymphocytic leukemia.
    Giannopoulos, Krzysztof
    Krober, Alexander
    Dmoszynska, Anna
    Rolinski, Jacek
    Dohner, Hartmut
    Stilgenbauer, Stephan
    Schmitt, Michael
    BLOOD, 2006, 108 (11) : 785A - 785A
  • [9] Receptor for hyaluronic acid-mediated motility (RHAMM, CD168) expression is prognostically important in both nodal negative and nodal positive large cell lung cancer (vol 69, pg 368, 2015)
    Augustin, F.
    Fiegl, M.
    Schmid, T.
    JOURNAL OF CLINICAL PATHOLOGY, 2015, 68 (06)
  • [10] THE PROGNOSTIC SIGNIFICANCE OF RECEPTOR FOR HYALURONIC ACID MEDIATED MOTILITY (RHAMM) EXPRESSION IN PEDIATRIC ACUTE LEUKEMIAS
    Jacob, Jerusha Samuela
    Shalini, Sai
    Suman, Febe Renjitha
    Scott, Julius Xavier
    PEDIATRIC BLOOD & CANCER, 2016, 63 : S26 - S27
12345